Omega-3s Revealed

Researchers have long known omega-3 fatty acids help reduce inflammation. Now they know how.

by Linda RichardsPosted 2/12/07

Understanding how your body benefits from eating omega-3 fatty acids is an important part of understanding why you should eat them. But, until recently, no one really knew what made omega-3s so beneficial. Researchers, however, have uncovered the secret of omega-3 fatty acids. A study at Brigham and Women’s Hospital in Boston revealed that omega-3s actually convert into compounds that are 10,000 times more potent than the original fatty acids themselves. So what does this mean to us? The new compounds include resolvins, which help bring the inflammatory response to an end, says the study’s lead researcher, Charles Serhan, PhD, director, Center for Experimental Therapeutics and Reperfusion Injury at Harvard Medical School, Boston. Continue reading ...

New Drug for Arthritis?

New drug for arthritis?: Merck seeking FDA approval for Arcoxia, a chemical relative of Vioxx, which was linked to heart attacks

Kathleen Kerr, Newsday, Melville, N.Y.

Mar. 21, 2007 -- In a bid to recapture a piece of the arthritis pain-relief market, Merck & Co. is seeking government approval for Arcoxia, a chemical relative of Vioxx, the drug pulled off drugstore shelves in 2004 after being linked to heart attacks.

In its last full year on the market, Vioxx brought in about $2.5billion in sales. If the Food and Drug Administration approves Arcoxia, Merck could recoup some of those sales.

On April 12 an FDA advisory panel will consider approval of Arcoxia for osteoarthritis; it is already sold in 62 other countries. The FDA usually follows advisory panel recommendations. Continue reading ...

FDA Whistle Blower Blasts New Arthritis Drug

FDA whistle-blower Graham blasts new Merck arthritis drug

Updated 9/12/2006 9:51 PM ET

By Rita Rubin, USA TODAY / Health & Behavior

The arthritis drug that Merck has developed to compete with Celebrex may be as risky for the heart as Vioxx, writes Food and Drug Administration whistle-blower David Graham in an editorial posted online Tuesday by a medical journal.

In considering whether Arcoxia should be approved, "the FDA, academia, and the medical research enterprise are once again faced with the opportunity to forsake common sense by willfully accepting misdirection and disinformation presented in the guise of science," Graham writes on the Journal of the American Medical Association's website. Continue reading ...